{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:01:04Z","timestamp":1778209264163,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Germline pathogenic variants in <jats:italic>BRCA1\/2<\/jats:italic> have been established in hereditary breast and ovarian cancer (HBOC) syndrome and result in significantly elevated lifetime risk of ovarian cancer. Risk reduction interventions are presently the only effective means of improving survival and specialized counselling clinics have been established as an effective means of aiding this population in navigating complex decisions surrounding these interventions. This study sought to evaluate patient perceptions of a specialized counselling clinic for patients with HBOC Syndrome and referral patterns to this clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We completed a retrospective review of 200 patients with HBOC in Nova Scotia, Canada seen through Maritime Medical Genetics Services between 2006 and 2016. Data were collected on referral pattern to the Hereditary Gynaecologic Risk Reduction Clinic (HGRRC), demographics, health history, and uptake of risk-reducing interventions. Participants were invited to complete a questionnaire about their experience.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>156\/200(78%) women were referred to HGRCC and 135\/156 (85.9%) of those referred attended their appointment. 124\/200 (62%) were over age 40 at the time of testing. The mean time from referral to HGRCC appointment was 134.68\u00a0days (SD 85.78). 85\/135 (63%) underwent risk-reducing bilateral salpingo-oophorectomy following their HGRCC appointment. The questionnaire was completed by 94\/188 (50.3%) women. Most participants found information received from genetics clinics (81\/94; 91%) and genetic counsellors (87\/94; 95%) most helpful in making choices around risk-reduction strategies. 83\/94 (88%) participants felt they had sufficient information to make an informed decision.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The majority of women with HBOC in Nova Scotia during the study period were referred to and counselled through HGRRC. Genetic counselling was found most valuable in risk-reduction decision making, which highlights the importance of a multidisciplinary team. Patients viewed this clinic as an effective care model to support informed choice about risk-reducing intervention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-022-01844-5","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T12:03:02Z","timestamp":1656504182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006\u20132016"],"prefix":"10.1186","volume":"22","author":[{"given":"Lauren","family":"Adolph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Warias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Stairs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Collins-McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette","family":"Penney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Kieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"11","key":"1844_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"1844_CR2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (plco) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295\u2013303.","journal-title":"JAMA"},{"issue":"10022","key":"1844_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945\u201356.","journal-title":"Lancet"},{"issue":"12","key":"1844_CR4","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","volume":"46","author":"S Iodice","year":"2010","unstructured":"Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275\u201384.","journal-title":"Eur J Cancer"},{"issue":"15","key":"1844_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547\u201353.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1844_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ygyno.2015.08.020","volume":"139","author":"V Giannakeas","year":"2015","unstructured":"Giannakeas V, Sopik V, Shestopaloff K, Iqbal J, Rosen B, Akbari M, et al. A model for estimating ovarian cancer risk: application for preventive oophorectomy. Gynecol Oncol. 2015;139(2):242\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1844_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1701-2163(16)32349-0","volume":"29","author":"D Horsman","year":"2007","unstructured":"Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, et al. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can. 2007;29(1):45\u201360.","journal-title":"J Obstet Gynaecol Can"},{"issue":"2","key":"1844_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1844_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1200\/JCO.2011.38.6060","volume":"30","author":"AW Kurian","year":"2012","unstructured":"Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, et al. Online tool to guide decisions for BRCA1\/2 mutation carriers. J Clin Oncol. 2012;30(5):497\u2013506.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1844_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jama.2019.10987","volume":"322","author":"DK Owens","year":"2019","unstructured":"Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement. JAMA. 2019;322(7):652\u201365.","journal-title":"JAMA"},{"issue":"13","key":"1844_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1002\/cncr.29321","volume":"121","author":"JL Walker","year":"2015","unstructured":"Walker JL, Powell CB, Chen L, Carter J, Bae J, Victoria L, et al. Society of gynecologic oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108\u201320.","journal-title":"Cancer"},{"issue":"3","key":"1844_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10689-012-9530-x","volume":"11","author":"NJ Engel","year":"2012","unstructured":"Engel NJ, Gordon P, Thull DL, Dudley B, Herstine J, Jankowitz RC, et al. A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer. Fam Cancer. 2012;11(3):419\u201327.","journal-title":"Fam Cancer"},{"key":"1844_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/jmg.2009.072728","volume":"47","author":"EK Bancroft","year":"2010","unstructured":"Bancroft EK, Locke I, Ardern-Jones A, D\u2019Mello L, McReynolds K, Lennard F, et al. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of brca1 and brca2 carriers-implications for oncogenetics practice. J Med Genet. 2010;47:486\u201391.","journal-title":"J Med Genet"},{"issue":"9","key":"1844_CR14","first-page":"549","volume":"18","author":"R Yerushalmi","year":"2016","unstructured":"Yerushalmi R, Rizel S, Zoref D, et al. A dedicated follow-up clinic for BRCA mutation carriers. Isr Med Assoc J. 2016;18(9):549\u201352.","journal-title":"Isr Med Assoc J"},{"key":"1844_CR15","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2021. Toronto: Canadian Cancer Society; 2021. http:\/\/www.cancer.ca\/Canadian-Cancer-Statistics-2021-EN. Accessed 20 Apr 2022."},{"key":"1844_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"1844_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"1","key":"1844_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/gtmb.2008.0067","volume":"13","author":"MS Beattie","year":"2009","unstructured":"Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mole Biomark. 2009;13(1):51\u20136.","journal-title":"Genet Test Mole Biomark"},{"issue":"21","key":"1844_CR19","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-09-2953","volume":"16","author":"S Miller","year":"2010","unstructured":"Miller S, Roussi P, Daly M, Scarpato J. New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res. 2010;16(21):5094\u2013106.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1844_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121(1):15\u201321.","journal-title":"Br J Cancer"},{"issue":"1","key":"1844_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","volume":"150","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018;150(1):85\u201391.","journal-title":"Gynecol Oncol"},{"key":"1844_CR22","first-page":"1","volume-title":"Genetic\/familial high-risk assessment: breast, ovarian and pancreatic","author":"National Comprehensive Cancer Network","year":"2021","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast, ovarian and pancreatic. NCCN Clinical Practice Guidelines in Oncology; 2021. p. 1\u2013119."},{"issue":"13","key":"1844_CR23","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347\u201361.","journal-title":"JAMA"},{"key":"1844_CR24","unstructured":"Statistics Canada. Nova Scotia and Canada. Census profile. 2016 Census. Statistics Canada Catalogue no. 98-316-X2016001. Ottawa. Released November 29, 2017."}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-01844-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01844-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T12:04:10Z","timestamp":1656504250000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-01844-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1844"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-01844-5","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"29 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received REB approval (Nova Scotia Health Authority REB #1022959). All questionnaire respondents provided informed consent. All research was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors LA, AW, JS, KCM, LP declare that they have no competing interests. Author KK has received research funding from Merck, AstraZeneca Canada Inc. and Medtronic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}